|
|
 | |||||||||||||||||||||||||||||||||||||||||||||||
 | |||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||
Background In this trial of the treatment of newly diagnosed multiple myeloma, we compared a protocol that entailed a hematopoietic stem-cell autograft followed by an allograft from an HLA-identical sibling with a protocol of tandem autografts.
Methods We enrolled 162 consecutive patients with newly diagnosed myeloma who were 65 years of age or younger and who had at least one sibling. All patients were initially treated with vincristine, doxorubicin, and dexamethasone, followed by melphalan and autologous stem-cell rescue. Patients with an HLA-identical sibling then received nonmyeloablative total-body irradiation and stem cells from the sibling. Patients without an HLA-identical sibling received two consecutive myeloablative doses of melphalan, each of which was followed by autologous stem-cell rescue. The primary end points were overall survival and event-free survival.
Results After a median follow-up of 45 months (range, 21 to 90), the median overall survival and event-free survival were longer in the 80 patients with HLA-identical siblings than in the 82 patients without HLA-identical siblings (80 months vs. 54 months, P=0.01; and 35 months vs. 29 months, P=0.02, respectively). Among patients who completed their assigned treatment protocols, treatment-related mortality did not differ significantly between the double-autologous-transplant group (46 patients) and the autograft–allograft group (58 patients, P=0.09), but disease-related mortality was significantly higher in the double-autologous-transplant group (43% vs. 7%, P<0.001). The cumulative incidence rates of grades II, III, and IV graft-versus-host disease (GVHD) combined and of grade IV GVHD in the autograft–allograft group were 43% and 4%, respectively. Overall, 21 of 58 patients (36%) were in complete remission after a median follow-up of 38 months (range, 10 to 72) after allografting. Of the 46 patients who received two autografts, 25 (54%) died.
Conclusions Among patients with newly diagnosed myeloma, survival in recipients of a hematopoietic stem-cell autograft followed by a stem-cell allograft from an HLA-identical sibling is superior to that in recipients of tandem stem-cell autografts. (ClinicalTrials.gov number, NCT00415987
[ClinicalTrials.gov]
.)
Source Information
From San Giovanni Battista Hospital, University of Turin, Turin (B.B., M.R., L.G., R. Sorasio, P.O., S.B., M.M., A.P., M.B.); the University of Udine, Udine (F.P., R.F.); Santa Croce e Carle Hospital, Cuneo (N.M., A.G.); Santi Antonio e Biagio Hospital, Alessandria (B.A., A.L.); the Institute for Cancer Research and Treatment, Candiolo (F.C.-S., M.A.); and San Giovanni Battista Hospital and Centro Prevenzione Oncologica Regione Piemonte, Turin (I.B., G.C.) — all in Italy; and the Fred Hutchinson Cancer Research Center, University of Washington, Seattle (R. Storb).
Address reprint requests to Dr. Bruno at the Divisione Universitaria di Ematologia, Azienda Ospedaliera San Giovanni Battista, Via Genova 3, Turin 10126, Italy, or at benedetto.bruno{at}unito.it.
Related Letters:
Allografting or Autografting for Myeloma
van Rhee F., Crowley J., Barlogie B., Rajkumar S. V., Kyle R. A., Moreau P., Harousseau J.-L., Attal M., Bruno B., Ciccone G., Boccadoro M.
Extract |
Full Text |
PDF
N Engl J Med 2007;
356:2646-2648, Jun 21, 2007.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |
Previous
